systemic lupus erythematosus
Rheumatology · 2019–2024
5decisions
2medicines
5carried consumer input
169individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| anifrolumab Treatment of patients with severe systemic lupus erythematosus (SLE) with high disease activity (SLEDAI-2K ≥10) despite standard of care (triple therapy… | Mar 2024 | Recommended with restriction | 142 individuals |
| anifrolumab Treatment of adult patients with severe systemic lupus erythematosus (SLE) with high disease activity (SLEDAI-2K ≥10) despite standard of care (SOC). | Mar 2023 | Not recommended | 11 individuals Australian Rheumatology Association |
| anifrolumab Treatment of adult patients with systemic lupus erythematosus (SLE) with a high degree of disease activity despite standard of care, added to standard therapy… | Jul 2022 | Not recommended | input received Musculoskeletal Australia · Lupus Australia · Community Controlled Health Organisation · Australian Rheumatology Association |
| belimumab Add-on therapy for active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity despite standard therapy. | Jul 2020 | Not recommended | 7 individuals |
| belimumab Active auto-antibody positive systemic lupus erythematosus (SLE) with a high degree of disease activity, despite defined ongoing standard of care. | Nov 2019 | Not recommended | 9 individuals |
Who spoke
Australian Rheumatology Association · Musculoskeletal Australia · Lupus Australia · Community Controlled Health Organisation
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 5 of 5 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.